The Marketing Advantage

JUNE 27, 2022

June 27, 2022 The payout curve against which a sales force is compensated has tremendous ability to motivate the sales force to drive sales—so much so that we are dedicating a three-part series to biopharma payout curve design. PAYOUT THRESHOLD Start very early to immediately engage the sales force.

Biopharma 52

Biopharma Sales Marketing Competition 52

The Marketing Advantage

NOVEMBER 30, 2021

The severity and impact of the Omicron variant is still being assessed, forcing biopharma companies to grapple with immense uncertainty during one of the most important planning periods of the year, including 2022 sales incentive compensation planning. TERRITORY-LEVEL CONTINGENCY PLAN. 100%/80%) in order to make the territory whole.

Sales 52

Sales Biopharma Competition Medical 52

pharmaphorum

OCTOBER 20, 2022

Together, these groups compile vast amounts of data, including rich information on patient populations, target customers, and the competitive landscape. How can we maximise marketing, sales, medical, access, and other teams’ efforts while making their jobs easier? Truly understanding the competitive landscape and market environment.

Competition 98

Competition Marketing Pharma Biopharma 98

pharmaphorum

AUGUST 5, 2022

Over the past 15 years, more than 60% of asset growth among the top 30 biopharma companies came from acquisitions. The pace of innovation in biopharma has rocketed over the last two years, with vaccines, new antivirals, and therapies delivered at an unprecedented pace.

Biopharma 52

Biopharma Marketing Pharma Relationship management 52

Pharmaceutical Technology

DECEMBER 20, 2022

The growing competition from generic drugs presents challenges for the top 20 players placing pressure on drug prices. Despite a drop in sales from Regeneron’s COVID-19 antibody, REGEN-COV, due to ineffectiveness against the Omicron variant, the company experienced record US sales of $1.63 trillion in Q2 2022 to $3.14

Biopharma 52

Biopharma Marketing Sales Competition 52

pharmaphorum

NOVEMBER 24, 2022

Mirati Therapeutics is the subject of takeover speculation in the biopharma sector once again, as it waits for the FDA’s decision on its KRAS inhibitor adagrasib in non-small cell lung cancer (NSCLC). Mirati has declined to comment on the speculation.

Pharma 105

Pharma Biopharma FDA Competition 105

MedCity News

OCTOBER 12, 2023

European Union regulators ordered Illumina to divest Grail. Illumina is appealing antitrust findings in Europe and the U.S., but the DNA sequencing giant revealed that divesting all or part of Grail is an option even if it wins both legal challenges.

Sales 122

Sales Competition Biopharma 122

Pharmaceutical Technology

FEBRUARY 8, 2023

The top 20 companies in the global biopharma industry saw 5.4%* aggregate market capitalization from $3.43 The company’s blockbuster immunotherapy oncology drug, Keytruda, a monoclonal antibody that targets PD-1, continues to reap record sales with an analyst consensus global sales forecast of $20.8 trillion to $3.61 to $365.84.

Marketing 78

Marketing Biopharma Sales Pharma 78

Pharmaceutical Technology

JUNE 29, 2022

According to Laursen, the decision to break into speciality enzymes was based on a look into the future of the biopharma market and an important assessment of how the company believes it can make a genuine difference. That is a key competitive advantage,” says Laursen. “We The impact could be huge for the biopharma industry.

Specialization 118

Specialization Biopharma B2B Sales Manufacturing 118

The Marketing Advantage

MAY 8, 2023

Nevertheless, launching a rare disease product continues to be incredibly challenging; in extreme cases, companies have even chosen to cease all commercial sales efforts for their rare disease treatment. However, patients may see several physicians before being diagnosed, meaning a small sales force may need to service many physicians.

Sales 52

Sales Physicians Consulting Education 52

The Marketing Advantage

SEPTEMBER 7, 2021

In parallel with this growing industry-wide complexity has been the call to further simplify sales compensation plans. Bridging this increasingly growing divide is not easy and raises the question of what truly makes a sales compensation plan simple. ATTRIBUTE 2 Simple to administer. Simple to understand. Simple to administer.

Sales 52

Sales Biopharma Marketing Management 52

pharmaphorum

JANUARY 3, 2023

The Italian biopharma said it had decided to press ahead with the new study after assessing results from 100 patients with TRS in open-label studies who received the glutamate modulator drug as an add-on to their current therapy for more than six months. ” The new data could accelerate partnering efforts of the drug this year.

Side effects 105

Side effects Biopharma Patients Competition 105

The Marketing Advantage

JULY 10, 2023

July 10, 2023 One of the functions most critical to maximizing the productivity and efficiency of the sales force’s efforts is call planning —how often a physician target should be seen by a sales representative. Why Don’t Sales Representatives Follow Call Plans? Why Don’t Sales Representatives Follow Call Plans?

Sales 40

Sales Consulting Specialization Prospecting 40

The Marketing Advantage

MARCH 9, 2021

March 9, 2021 Critical to optimizing sales force productivity and efficiency is identifying the right HCP and/or account targets. However, in the complex pharma, biotech and medical device landscape, the easy way of targeting HCPs is, unfortunately, not the right way in most circumstances, and ultimately diminishes sales and adoption.

Sales 52

Sales Competition Marketing Biopharma 52

pharmaphorum

JANUARY 24, 2023

A just-published report from the Medicines Manufacturing Industry Partnership (MMIP) – set up by the UK government and biopharma industry in 2014 to drive growth in the category – says the sector has the potential to be a driver for the UK economy in the next decade.

Manufacturing 111

Manufacturing Medicine Government Pharmaceutical manufacturing 111

The Marketing Advantage

NOVEMBER 13, 2023

November 13, 2023 Two critical elements that inform how biopharma sales representatives sell to HCPs are (1) the prescribing behavior exhibited by the HCP, or behavioral segment , and (2) the HCP’s loyalty to the products they prescribe. Consider a dominant single prescriber. make the prescriber become a dominant dual prescriber).

Consulting 52

Consulting Sales Biopharma Competition 52

pharmaphorum

DECEMBER 28, 2022

M&A is an integral part of the lifecycle of pharma companies and a key strategy to future-proof larger players, driving R&D activities and innovation for a competitive product pipeline. In 2018, over 60% of all new molecular entities came from smaller biopharma firms, compared with just over 30% in 2009.

Pharma 119

Pharma Pharmaceutical manufacturing Pharmaceutical Manufacturing 119

European Pharmaceutical Review

JUNE 15, 2023

Sales in the small molecule innovator CDMO market is expected to grow at a compound annual growth rate (CAGR) of 6.4 Accelerating advancement of research and technology in biopharma are generating opportunities for the industry to develop innovative small molecule drugs. billion in 2023 and $89.43 billion in 2033.

Marketing 52

Marketing Competition Manufacturing Biopharma 52

PM360

NOVEMBER 27, 2023

I recently sat down with Erica Taylor, PhD, Vice President and Chief Marketing Officer at Genentech, to talk about the future of biopharma marketing and creating more meaningful content. Now, due to the highly competitive environment, the process is truncated to 12-18 months.

Marketing 105

Marketing Customer Relationship Management Relationship management Education 105

Clarivate

JULY 5, 2023

The Biosimilars Forum has hailed 2022 as a watershed year that could create a more competitive U.S. Clarivate research indicates biosimilar competition will drive down prices and relative market share of HUMIRA ® in the U.S. By end of year, as many as ten adalimumab biosimilars could be on the U.S. from 91% in 2023 to 36% by 2031.

Marketing 97

Marketing Physicians Manufacturing Competition 97

Clarivate

OCTOBER 17, 2024

Companies need to carefully assess the value of the assets being acquired or licensed, considering factors such as the stage of development, market potential, the competitive landscape and intellectual property protection.

Pharma 59

Pharma Competition Marketing Healthcare 59

Clarivate

MARCH 12, 2024

For the approximately 10% of biopharma candidates that actually manage to make it to clinical trials, many fail to achieve enough revenue once they reach the market to justify the R&D effort. In fact, one-third of drugs launched over a recent 10-year period fell short of sales expectations.

Government 52

Government Marketing Physicians Biopharma 52

Clarivate

JANUARY 23, 2024

forecast peak sales per asset versus the cost of developing an asset or an output measure such as the number of global first world launches). In addition, R&D productivity analyses are in some way associated with actual or future launches or a consequence of the launch, such as resulting sales.

Pharma 52

Pharma Sales Consulting Pharmaceutical 52

pharmaphorum

JANUARY 27, 2023

There is global capital out there for us to attract, as well as finance in the City of London [that] we need to unlock, but competition is fierce.” Bates continued: “We expected a fall in investment following two bumper years, but it should still be considered a warning.

Pharma 52

Pharma Manufacturing Medicine Biopharma 52

Quantified

JANUARY 3, 2023

You are going to see a dramatic change in leadership’s urgency to leverage AI This new creative AI era will fuel massive advances in personalized customer service, drive new business models, improve real-time modeling ( Southwest Airlines ) and pave the way for breakthroughs in healthcare and biopharma from Google ‘s DeepMind.

Biopharma 40

Biopharma Media Competition Training 40

Clarivate

OCTOBER 25, 2023

exclusions exist for orphan drug designation and biosimilar competition ). Under buy and bill (B&B) in Medicare Part B, physician practices profit from reimbursement (historically Average Sales Price + 6% before sequestration) as well as rebates and discounts negotiated with manufacturers for hitting volume levels.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Veeva

APRIL 28, 2024

As the pharmaceutical landscape grows more dynamic and competitive, life sciences companies are increasingly expected to develop more innovative brand launches, whilst juggling more complexity in marketing and interactions with healthcare professionals (HCPs).

Management 52

Management Marketing Distribution Biopharma 52

PM360

APRIL 22, 2024

With an ever- increasing demand for their time and attention, it is more difficult than ever for biopharma representatives to convey their message to the physician audience. In one survey, only 12% of HCPs said they felt biopharma companies are very effective at providing HCP education and training to them.

Education 59

Education Physicians Healthcare Healthcare 59

Pharmaceutical Technology

NOVEMBER 23, 2022

The US still dominates the biopharma sector with more than $378bn in annual drug sales and an approximate capacity of 30% of global manufacturing. Hamilton offers more competitive prices than Toronto and the city is only an hour away from its larger neighbour. City Competitiveness Index. ft2 in Toronto 1.

Marketing 52

Marketing Manufacturing Transportation Government 52

Clarivate

DECEMBER 14, 2023

With analysts estimating that obesity drug sales could top $100 billion annually , concerns over the financial hit is likely why plans covering 30% of lives do not reimburse Wegovy, per Clarivate Fingertip Analytics data. The arrival of a second drug may drive PBMs to expand coverage in exchange for aggressive rebates.

Marketing 52

Marketing Healthcare Healthcare Insurance 52